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Abstract
Background: Substance use disorders are associated with poorer clinical outcomes in patients with schizophrenia.
There is no specific treatment for amphetamine or cannabis use disorder, but methadone and buprenorphine are
used as replacement therapy in the treatment of opioid dependence. Our aim was to study whether patients with
schizophrenia have received opioid replacement therapy for their opioid use disorder.
Methods: The study sample consisted of 148 individuals diagnosed with schizophrenia who were in involuntary
psychiatric treatment as forensic patients in Finland in 2012. The proportion of the study sample with comorbid
opioid use disorder having received opioid replacement therapy prior to their forensic psychiatric treatment was
compared to the available information of opioid dependent patients in general. The data were collected from
forensic examination statements, patient files and other medical registers retrospectively.
Results: Of the study sample, 15.6% (23/148) had a history of opioid use disorder, of whom 8.7% (2/23) had
received opioid replacement treatment (95% confidence interval (Cl): 1.1–28.0), even though opioid use disorder
had been diagnosed in the treatment system. According the available information the corresponding proportion
among patients with opioid use disorder and using substance use disorder services was 30.4% (565/1860, 95% Cl:
28.3–32.5). The fraction of patients receiving opioid replacement therapy was significantly lower among patients
with schizophrenia (p = 0.022).
Conclusions: Opioid replacement therapy was seldom used among schizophrenia patients who were later ordered
to involuntary forensic psychiatric treatment. More attention should be paid to the possible use of opioids when
planning treatment for patients with schizophrenia.
Trial registration: Our study is not a randomized controlled trial (but a register-based study); thus the trial registration
is not applicable.
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Background
Schizophrenia is a severe mental disorder, which affects
the individual’s way of thinking, feeling and behaving in
many ways. It is one of the leading causes of years lived
with disability [1]. About half of the patients with schizo-
phrenia have problems with substance use [2–4].The
prevalence rates for the comorbidity vary between coun-
tries. In general, the prevalences are found to be lower in
Europe than in the United States [5]. These comorbidities
are associated not only with poorer clinical outcomes but
also with the increased morbidity and mortality.
Patients with comorbid substance use disorder are at a
higher risk for medication noncompliance, they have
more re-hospitalizations, they have poorer quality of
life, and the rate of suicidality and violent behavior is
higher [4–12].
Most of the studies concerning comorbid substance
use disorder among patients with schizophrenia are fo-
cused on the assumed association between cannabis use
and the development of schizophrenia, and less attention
has been paid to other specific substances, although opi-
oids are the most prevalent drugs among drug users in
the European Union [13]. Also, when estimating the
burden of disease consequent of drug dependence, the
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highest estimated global burden was attributable to
opioid dependence [14]. Opioid users have a 15-fold
increased risk of all-cause mortality when compared to
the general population [15], and the risk is still high if
the patient is on a waiting list for replacement treat-
ment, indicating an urgent need of the therapy [16].
Detoxification is not an adequate treatment of sub-
stance dependence on its own, since relapse is almost
inevitable. Opioid replacement therapy, combined with
psychosocial assistance, has been found to be the most
effective of the treatment options available [17]. World
Health Organization (WHO) has stated that pharma-
cological treatment of opioid dependence should be
accessible to all those in need, including those incar-
cerated and in other closed institutions. Also, according
to National Institute for Health and Care Excellence [18],
comorbid mental health problems should be treated
alongside opioid dependence.
No specific treatment for amphetamine or cannabis
use disorder has been demonstrated, but buprenorphine
and methadone are used as a replacement therapy in the
treatment of opioid dependence. Research has shown
the effectiveness of buprenorphine and methadone re-
placement therapy in reducing mortality and criminal
activity, improving physical and mental health, and in
decreasing illicit drug activity [19–27], but there are only
few studies on opioid replacement therapy among schizo-
phrenia patients with comorbid opioid use disorder. Also,
there are no previous studies on the prevalence of this
treatment among persons with schizophrenia compared
to other persons with opioid use disorder.
The combination of methadone and clozapine was
successful when five schizophrenia patients with opioid
addiction were treated [28]. Also, according to the study
of Gerra et al. [29], the rate of heroin-addicted patients
with schizophrenia who remained in replacement treat-
ment and who obtained early full abstinence was higher
when olanzapine was used compared to those who were
treated with haloperidol. It has been stated that treat-
ment of comorbid opioid use disorder in patients with
schizophrenia should be a combination of case manage-
ment and medical therapy [30]. In a study of adherence
to methadone maintenance treatment, persons with a se-
vere mental disorder as schizophrenia have significantly
higher adherence to treatment, maybe because they
are more closely monitored by health or social care
professionals when compared to those without this co-
morbidity [31].
Our aim was to investigate the prevalence of opioid re-
placement therapy obtained by patients with schizophre-
nia and comorbid opioid use disorder prior to their
forensic psychiatric treatment, and in other words, to
find out whether this patient group had received similar
pharmacological treatment for their opioid use disorder
as compared to other patients using substance use dis-
order services.
Methods
The permission for the study was granted by the Board
of Niuvanniemi Hospital and by the Finnish National
Institute for Health and Welfare. The study sample in-
cluded an annual cohort of patients with schizophrenia
spectrum disorder who were in involuntary treatment
in Niuvanniemi Hospital needing high-security hos-
pital placement as forensic patients at any time in
2012. Niuvanniemi Hospital is a state mental hospital
which is in charge of forensic psychiatric services and
forensic mental examinations for the needs of the
whole of Finland (www.niuva.fi). Opioid use disorder
was defined as harmful use of opioids or opioid de-
pendence. In Finland, the official diagnostic classifica-
tion is ICD-10, according to which all of the diagnoses
were made. In ICD-10, harmful use is described as a
pattern of a psychoactive substance use that is causing
physical or mental damage to health, and dependence
as a cluster of behavioral cognitive, and physiological
phenomena that develop after repeated substance use
and that typically include a strong desire to take the
drug, difficulties in controlling its use, persisting in its
use despite harmful consequences, a higher priority
given to drug use than to other activities and obliga-
tions, increased tolerance, and sometimes a physical
withdrawal state [32]. All data concerning the study
sample was collected retrospectively from forensic
examination statements and patient files by the same
person (K.K.), and it was checked if the criteria for
harmful used or dependence were fulfilled.
In international comparison the Finnish practice of
mental examinations can be considered to be very thor-
ough. Preliminary information concerning persons under-
going mental examination is obtained from the persons
themselves and, health care units in charge of previous
treatment, and also, with their consent, from their family
members, friends, employers etc. (www.niuva.fi). A com-
parison group to contrast the study sample with was from
the available information, according to which 565 of the
1860 persons (30.4%) using substance use disorder ser-
vices in 2011 were receiving replacement therapy. In this
group, the mean age was 33, and the median age 32 years
[33]. No individual level data such as age was available
from the individuals in the national database of substance
use disorder patients. Statistical analysis was conducted
using the Fisher exact test. It was considered appropriate
since the sample sizes were small.
Results
The cohort of forensic patients consisted of 148 persons,
of whom 95.3% (141/148) were male, 56.1% (83/148)
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had paranoid, 20.3% (30/148) undifferentiated, 3.4% (5/
184) hebephrenic, and 4.1% (6/184) some other type of
schizophrenia. A total of 24/184 (16.2%) had a schizoaf-
fective disorder (Table 1). The mean age of the sample
was 42.8 years, and the mean age at the time of offense
was 30.9 years. The average time from the offense lead-
ing to mental examination was about four years.
Of the study sample, 15.6% (23/148) had a history of
opioid use disorder documented in health care records,
of whom and 8.7% (2/23) had received opioid replace-
ment treatment (95% Cl:1.1–28.0).The corresponding
proportion among patients with opioid use disorder
using substance use disorder services was 30.4% (565/
1860), (95%Cl: 28.3–32.5) (Table 2). The fraction of pa-
tients receiving replacement treatment was significantly
lower among the cohort of forensic patients (p = 0.022).
Discussion
The present study evaluates the prevalence of opioid re-
placement therapy among patients with schizophrenia
and comorbid opioid use disorder. Many studies have fo-
cused to the nature of the relationship between cannabis
use and schizophrenia but less attention has been paid
to other specific substances. The burden of disease con-
sequent of drug dependence is highest when it is ques-
tion of opioid use disorder [34], and patients diagnosed
with this comorbidity belong to the costliest group of all
patients with opioid use disorder [35]. Evidence based
medications for opioid dependence have been shown to
be helpful in patients with severe mental disorder [36],
but on the other hand, the retention rate in opioid re-
placement therapy among patients with schizophrenia at
12 months was less than 10%, and over half of the pa-
tients had illicit opioid use during the treatment accord-
ing to the study of Gerra et al., 2006 [37]. Patients with
this comorbidity are more likely to have been homeless
and to have had a recent psychiatric hospitalization
when compared to other patients [38]. In an Iranian de-
scriptive study of 100 patients with schizophrenia, as
much as half of the patients had opioid dependence dis-
order based on DSM-IV criteria. This high prevalence is
probably influenced by the easy access and low price of
opioids in Iran. However, it was speculated that patients
with schizophrenia may use opioids as self-medication to
reduce positive symptoms [39]. The antipsychotic effect-
iveness of opioid agonists is highlighted in a recent review,
in which it is suggested that the use of opioid agonists de-
serves reconsideration because of their anticraving cap-
ability and effectiveness on the psychopathological level
[40]. It has also been stated that specific groups, including
patients with psychiatric comorbidities, may benefit from
optimized and higher doses of buprenorphine to ensure
sufficient dosing [41]. It is relevant to combine anti-
psychotic and opioid agonist medications with psycho-
social support [38], since group counselling, contingency
management and long-term residential treatment have
been shown to have positive effects [42].
In our study, only two of the 23 patients with schizo-
phrenia and comorbid opioid use had received opioid re-
placement treatment prior to hospital treatment as
forensic patients. In comparison, the estimated propor-
tion of persons with opioid use disorder undergoing re-
placement therapy suggests a treatment coverage rate of
about 50% in the European Union [43]. In Finland, opi-
oid replacement treatment is typically initiated in in-
patient units, after which the clients are transferred to
social outpatient services or health centers. General
practitioners and pharmacies are also participating in
the treatment process. There is no other monitoring sys-
tem or register of clients in treatment but data collection
on a voluntary and anonymous basis by the centers for
prevention and treatment of addiction. Also, the cover-
age of replacement therapy in Finland may vary between
different regions. The proportion of opioid users using
substance abuse treatment services and receiving re-
placement therapy in 2011 was 30.4% of problem opioid
users using those services and the mean age of those
opioid users was 33.0 years [33]. Information did not
cover all substance abuse treatment units. It is not
known if the patients in the study sample or in the com-
parison group received other types of treatments. How-
ever, when the effect of adding psychosocial treatment
interventions to standard opioid agonist treatment pro-
grams was compared, it was found that psychosocial
treatment did not offer additional benefits in terms of
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retaining individuals in treatment, supporting abstin-
ence, or preventing relapse [44].
Mental health care and substance use disorder services
are often separated from each other, although the coord-
ination of different services is essential for successful
treatment of patients with dual diagnoses. In Finland,
substance use services are mostly provided by social wel-
fare. Integrated treatment might have benefits for redu-
cing the risk of violent behavior in these patients, since
additive genetic influences are shared between schizo-
phrenia, substance use disorder, and violent behavior.
Substance use disorder was defined as either harmful
use or dependence since in practice, harmful substance
use can be quite severe and sometimes it is challenging
to distinguish the two.
The information of persons with opioid use disorder
and their treatment is incomplete. In this study, it was
presumed that the information available was representa-
tive enough since information from different substance
use disorder services was not described to be missing
from systematic reasons.
Our study cohort is not a complete cohort of all of-
fender patients with schizophrenia in Finland. However, it
is well representative of patients requiring high-security
treatment, since vast majority of those patients are treated
in Niuvanniemi Hospital. Those who do not require
high-security treatment are located in medium-security
units of communities. According to our study, at least in
this subgroup of patients with schizophrenia, opioid ago-
nists were rarely used. The possible use of psychosocial
methods in treating opioid use disorder was not studied.
The latest estimate of individuals in Finland with problem
opioid use is from the year 2012 being 13,000–15,000
[45]. In Finland, the number of patients in opioid replace-
ment treatment has increased being about 30% higher in
2015 than in 2011 [46]. However, recent prevalence rates
of opioid users indicate increase at least in heroin use
[47], and so it can be expected that the number of opioid
users and opioid use disorders is going to grow. However,
the results of this study should be interpreted with care,
since the study sample is from the year 2012.
There are only a limited number of studies exploring
the relationship between opioids and psychoses, and the
causal connection between opioid use and psychosis is
still unclear. In general, the prevalence of psychoses and
comorbid opioid use has been found to be low [48]. In
the study of Dalmau and colleagues [49], the preva-
lence of psychotic illness was high among those with
amphetamine and cannabis use disorder but lower
among those with opioid use disorder. The lifetime
rate of opioid use among persons with schizophrenia
was about 12% according to Barnes et al. [2]. Comor-
bid psychotic illness and opioid use is associated with
increased mortality [50].
In guidelines for the pharmacological treatment of opioid
dependence [15, 51–53], schizophrenia is not mentioned to
be a contraindication for opioid replacement therapy.
Conclusions
Our results indicate that opioid use disorder is not, at least
pharmacologically, treated in the same way among patients
with schizophrenia as other persons with opioid use dis-
order. More attention should be paid to possible opioid use
when planning treatments for patients with schizophrenia,
since this patient group needs to have effective treatment
for their co-occurring mental and substance use disorders
to reduce morbidity, mortality, and risky behavior. Further
studies of the possible advantages and disadvantages of opi-
oid replacement therapy in patients with schizophrenia and
comorbid opioid use are needed.
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